Measuring Compensation in Neurodegeneration using MRI

Sarah Gregory¹,³, Jeffrey. D Long², Sarah J. Tabrizi¹, Geraint Rees³,⁴

¹ Huntington’s Disease Research Centre, UCL Institute of Neurology, London, UK
² Departments of Psychiatry and Biostatistics, University of Iowa, Iowa City, IA, USA
³ Wellcome Trust Centre for Neuroimaging, University College London, London, UK
⁴ Institute of Cognitive Neuroscience, University College London, London, UK

Contact for correspondence

Sarah Gregory, PhD
Huntington’s Disease Research Centre
UCL Institute of Neurology
2nd Floor, Russell Square House
10-12 Russell Square
London WC1B 5EH
E-mail: s.gregory@ucl.ac.uk
Tel: 020 3108 6309
Abstract

**Purpose of Review:** Despite signs of cortical and subcortical loss, patients with prodromal and early stage neurodegenerative disease are able to perform at a level comparable to the normal population. It is presumed that the onset of compensatory processes, that is, changes in brain activation within a function-specific network or in the recruitment of a region outside of the task-network underlies this maintenance of normal performance. However, in most studies to date increased brain activity is not correlated with indices of both pathology and performance and what appears to be compensation could simply be a symptom of the disease.

**Recent Findings:** MRI studies have explored compensation in neurodegenerative disease, claiming that compensation is evident across a number of disorders, including Alzheimer’s and Parkinson’s disease, but generally always in early stages; after this point compensation is generally no longer able to operate under the severe burden of disease pathology. However, none of these studies explicitly adopted a particular model of compensation. Thus, we also discuss our recent attempts to operationalise compensation for empirical testing.

**Summary:** There is clear evidence of compensatory processes in the early stages of neurodegenerative disease. However, for a more complete understanding, this requires more explicit empirical modelling.

**Keywords:** Compensation, Neurodegeneration, Magnetic Resonance Imaging
Introduction

During the early stages of neurodegeneration, normal performance levels are maintained despite neuronal loss and/or the presence of neurodegenerative pathologies. It has been suggested that this is due to compensatory processes, i.e. the adaptation of neural networks that allow the affected individual to exhibit normal behaviour in the presence of neuronal loss (1-3). Although plausible, compensation as a mechanism is likely to be highly complex and multi-faceted. To test confidently for the presence of compensatory processes in brain structure or activity requires full characterisation and modelling for explicit hypothesis testing. Here, we discuss the concept of compensation in neurodegeneration; examine recent studies that propose compensation in neurodegenerative populations using MRI; and finally, consider our recent attempts to operationalise compensation in Huntington’s disease (HD), a model neurodegenerative disorder.

Defining compensation

As yet, there is no established definition of compensation in neurodegeneration. Consequently, the term is often used indiscriminately to represent a diverse range of processes (indexed by often poorly defined changes in brain activity/connectivity) that could potentially represent compensation. For example, increased brain activity in a region within a task network in the presence of pathology is often deemed evidence of ongoing compensation. So too is activity in a brain region not typically associated with a particular function during task performance in an individual with neurodegeneration. However, such qualitative descriptions are often post-hoc and only support a partial characterisation of neural processes underlying compensation.

To describe compensation fully, brain activity or connectivity needs to be considered in the context of a larger model incorporating two additional key factors. The first is behaviour. Compensating brain activity/connectivity should assist in maintaining a normal level of behaviour; if it is below standard norms then it cannot be said that compensation is present, irrespective of changes in brain activity. Second is pathology; neuronal loss or indirect markers of neuronal loss due to neurodegenerative pathology. Much discussion has centred on compensation in the normal ageing population, which could be extrapolated to that within neurodegeneration cohorts (1, 4) (Figure 1). However, in healthy groups, these accounts cannot provide a complete characterisation of compensation as they focus only on the relationships between brain activity and behaviour, and do not also account for the structural change characteristic of neurodegeneration. As neurodegeneration is more prevalent in older individuals, disentangling the potential effects of ageing and neurodegeneration on putative effects of compensation requires an explicit model. In the studies discussed here, evidence of compensation mainly rests on increases in brain activity and/or behaviour.
Recent Studies of Compensation

Given the extensive investigation into neurodegeneration, there are only a limited number of studies providing evidence of compensation. This is testament to the complexity in both defining and testing compensation empirically. Of note in the studies discussed here, compensation is only evident in prodromal or mild cases of neurodegeneration; diminishing once neurodegenerative pathology becomes too severe. This supports the notion of a trajectory of compensation across neurodegenerative disorders, whereby the onset of the compensatory mechanism is triggered but eventually desists once disease reaches a certain level of pathological severity.

Compensation and fMRI

Changes in brain activity measured using task-related fMRI have been proposed as evidence of compensation in neurodegeneration. Most studies that have identified compensatory brain activity have highlighted task-based networks showing increased activation comparing either between patient and control groups or between two patient groups at different stages of neurodegenerative disease (5, 6). Such findings do not unequivocally indicate compensation; they could simply represent pathology-related change, particularly in cases where there is no congruent maintenance of performance. For example, in a recent study, a combined group of patients with Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD) displayed enhanced left prefrontal and amygdala activity compared to controls during emotionally-salient verbal working-memory (7). However, as task difficulty increased their task response times were significantly slower than that of controls. Equally, a similar group of MCI patients presented with increased resting-state functional connectivity between the parahippocampal gyrus and prefrontal cortex compared to controls, but this change was correlated with worsening episodic memory performance (8). In both cases, the absence of maintained performance suggests that increased brain activity/connectivity could be either partial/incomplete compensation or the effects of pathology.

In contrast, Amyotrophic Lateral Sclerosis patients demonstrate increased activation in the left superior frontal gyrus (SFG) while maintaining typical levels of memory filtering during a non-verbal working-memory task and despite frontal lobe atrophy (9). Similarly, non-medicated, cognitively-unimpaired Parkinson’s Disease (PD) patients exhibited increased activation bilaterally in the putamen and posterior insula while maintaining performance levels close to those of controls during working memory (10). Putaminal activation can be used successfully in such situations to distinguish PD patients from controls. While in both studies augmented brain activity is likely evidence of compensation, this is a post-hoc interpretation due to a lack of direct association between maintained performance and increased brain activity as a function of pathology.
The same absence of mechanistic characterisation is evident in a series of studies performed in early-stage non-medicated PD patients when compared to controls (11, 12). Increased activity in the bilateral parietal cortex and right SFG during set-shifting was presumed compensation for reduced ventrolateral prefrontal cortex activity (11). Similarly, increased putaminal and insular activation during working memory was presumed compensation for reduced dorsolateral prefrontal (DLPFC) connectivity (12). Although patient performance was maintained across both cognitive domains, there were some aspects where patients performed less well than controls. To understand fully the impact of this in light of the apparent compensatory behaviour requires more explicit investigation of the relationship between performance and brain activity.

**Functional Connectivity and Compensation**

Recently, there has been a move from characterising changes in task-related activity associated with a single network to examining a series of networks in the brain at rest. Functional connectivity analysis of resting-state fMRI data allows the investigation of some task-related networks in the brain at-rest, probing network connectivity changes related to neuronal loss. There has been particular focus on subsystems within the task-negative default mode network (DMN), a group of midline regions, most robust in the brain at-rest, and associated with self–referential thinking and memory (13-15). The DMN is affected early in AD with disease-related reductions in network connectivity (16-18) and investigation of the DMN in AD could provide insight into early systems-level changes that may occur. For example, patients from across the AD spectrum display reduced DMN connectivity beginning in the most highly-connected posterior regions, leading to the emergence of increased connectivity between posterior and anterior and ventral DMN subsystems respectively. Increased connectivity between posterior and ventral subsystems correlates with pathology: amyloid deposits and hippocampal volume and predicts AD onset (19). These purported compensatory processes may mark the beginning of a cascading network-wide failure that occurs prior to measurable structural and functional decline in AD. This is particularly interesting in terms of the trajectory of compensation – its onset and its cessation. However, there was no explicit testing of the correspondence between network subsystem connectivity and cognitive performance.

Other studies have investigated resting-state connectivity within the DMN in MCI and AD. As part of a comprehensive exploration of inferior parietal lobe (IPL) subnetwork connectivity, moderate AD patients with robust grey matter reductions compared to healthy controls display increased connectivity between the IPL and the posterior DMN, putatively compensating for the reductions in connectivity within DMN subnetworks and other IPL networks (20). Similarly, using Granger Causality, increases in directed connectivity from the posterior cingulate cortex (PCC) to the right temporal lobe and to the PCC from temporal regions might indicate compensatory activity in MCI patients (21), while high-performing AD patients also demonstrated increased occipital connectivity.
with three separate functional connectivity patterns including that of the anterior DMN and bilateral executive network when compared to low-performing AD patients; and with no comparable increase in the control group (22). Connectivity changes within the DMN are also indicative of PD pathology. A recent meta-analysis of the ReHo (regional homogeneity) method of analysing resting-state fMRI data - a similar approach to seed-based connectivity - showed in over 11 comparisons that it was within regions of the DMN that most changes were seen: bilateral IPL and medial prefrontal cortices when compared to controls (23).

The striatum is affected in the early stages of neurodegenerative disorders such as PD and HD and accordingly is a region of interest for connectivity analyses. There is evidence for increased putaminal connectivity with the cerebellum in mild to moderate PD patients, which correlates with motor performance improvement (24) and increased connectivity between the basal ganglia and the motor cortex in cognitively-unimpaired PD patients (25). Interestingly, one recent study investigated both PD and AD patients showing that in both cases reduced striatal connectivity was associated with improved cognitive performance. However, while plausible, it cannot be confirmed that this reduction necessarily contributed to improved cognitive performance, particularly given that similar patterns of connectivity were found in controls and therefore, may simply represent ageing (26).

Different mechanisms, i.e. potential compensation versus disease-related effects may underlie increased brain connectivity in subsystems of brain networks. For example, in a group of prodromal AD patients, increased connectivity between the retrosplenial cortex and the lateral occipital cortex compared to both controls and a subjective cognitively-impaired (SCI) group correlated with verbal memory performance, even when accounting for cognitive reserve factors (27). However, increased connectivity between the PCC and lingual gyrus correlates only negatively with attention suggesting a compensatory versus disease-effect dissociation in the two DMN subsystems.

In the same way, different mechanisms may underlie changes in connectivity in patients with varying disease subtypes. Heterozygous PD associated-gene-carriers, most of whom were not affected by the disease, for example, show increased connectivity between the salience network and DMN, which correlates with improved working memory performance (28). More severely affected homozygous PD gene-carriers, however, also show increased network connectivity between the salience and the right fronto-parietal network. This, however, correlates with a worsening of short term working memory performance signalling compensation onset in the early or mild to moderate stages of PD, which diminishes as pathology worsens. Similarly, using the putamen and the caudate as seeds for functional connectivity analyses, early-onset PD patients show increased connectivity between the striatum and parietal and frontal regions with that between the caudate and somatosensory cortex negatively correlated with clinical score. Late-onset PD patients correspondingly showed increased connectivity in the cerebello-striatal circuit and in this subgroup connectivity change between the
putamen and cerebellum is associated with lower clinical scores (29). Finally, recent studies have examined two other PD subtypes: postural instability and gait difficulty (PIGD) and tremor-dominant (TD). Here, there was a differentiation in patterns of increased connectivity from the subthalamic nucleus to the cerebellum in TD and the visual cortex in PIGD (30) with ‘hyperconnectivity’ between the motor cortex and IPL correlated with reduced behavioural impairment in TD compared to PIGD patients (31).

**Structural compensation**

Generally, MRI-based compensation is explored by examining changes in brain activity. Changes in anatomical connectivity or underlying white matter microstructure, as measured by diffusion-weighted imaging may (with caution in terms of biological interpretation), also give some clue as to the biological changes, such as demyelination and axonal degeneration that occur during neurodegeneration (32-34). Increased fractional anisotropy (FA; measure of white matter integrity in the main fibre direction), reduced diffusivity and increased density in callosal, projection and association tracts in low-disease load PD patients, for example, suggest considerable improvements in widespread white matter organisation (35). Furthermore, these changes are weakly correlated with motor symptom severity; i.e. greater white matter organisation means lower levels of motor dysfunction. As the substantia nigra (SN) is central to PD pathology, potential increased integrity in white matter tracts originating and projecting outside of this area could indicate compensation in the presence of SN degeneration; this is further supported by the absence of such changes in the severely affected group. Similar alterations were noted in white matter motor pathways including corticospinal and putaminal tracts in a different PD cohort (36). However, here there was increased diffusivity in the main direction of the principal fibre, indicating increased disorganisation and potentially axonal degeneration. It is possible that diffusivity in the pathways parallel to the main underlying fibre is simply higher than that in those perpendicular to it or alternatively, that increases in the number of streamlines (volume) represent reorganisation within the principal fibres leading to increased axial diffusivity. However, the lack of volumetric differences between controls and PD patients, plus an absence of correlations with motor severity makes the idea of ‘compensatory’ axonal sprouting unlikely.

**Compensation and Cognitive Reserve**

The difference between compensation and cognitive reserve is a complex one and often not explicitly characterised (1-4). Cognitive reserve refers to brain resilience in the presence of neuropathology and is largely influenced by education, lifestyle and socio-economic status (1, 3). It has been suggested that cognitive reserve is marked by augmented neuronal reserve allowing for increased efficiency in brain task-processing and potentially more activity in a task-network region; while compensation represents the brain’s ability to recruit task-unrelated regions to account for neuronal loss (37). Other
accounts, however, have suggested that compensation can also be present simply when activity in task-related regions increases (1, 38). In a recent study, the effects of cognitive reserve, measured by number of years in formal education, were explicitly tested in MCI and AD patients (39). Those with MCI and high levels of cognitive reserve displayed equivalent levels of verbal and short-term memory as controls, despite higher levels of AD pathology, i.e. medial temporal lobe atrophy. This performance was putatively sustained by a system of increased connectivity in fronto-parietal networks together with decreased connectivity in fronto-temporo-cerebellar networks and reduced posterior and thalamic efficiency. Those with AD diagnosis, however, display no such evidence of compensatory processes regardless of cognitive reserve levels. Cognitive reserve can have a profound effect on the recruitment of neural networks to facilitate normal behaviour in the presence of neuronal degeneration. However, once again in this example it is also possible that the extra connectivity could simply be symptomatic of MCI pathology.

**Operationalising Compensation**

Given the absence of an agreed way of formally characterising and thus determining the presence of compensation in neurodegeneration using brain imaging, we recently endeavoured to operationalise compensation and create a model that can explicitly test for the presence of compensatory processes (40). The model incorporated the three components that we consider important in fully characterising compensation; pathology, brain activity and behaviour and we investigated the interactions of these three components in premanifest HD (preHD) (Figure 2). HD may be thought of as a model neurodegenerative disorder for studying compensation. The certainty of onset allows investigation of biological and clinical changes in preHD many years prior to disease onset. Large observational follow-up studies allow us to examine our compensation model in a prospective preHD cohort with participants ranging from 15 years to one year before clinical diagnosis (Figure 2). We focussed exclusively on those with a high level of pathology, measured by volumetric change, a proven and very robust marker of HD progression, but who also demonstrated increased brain activity and maintained a normal level of behaviour. Using both task and resting-state fMRI, we demonstrated a pattern of asymmetrical compensation in the cognitive network (40). Specifically, in preHD gene-mutation carriers with the highest levels of pathology, we identified increased activity in the right parietal network during working memory and increased resting-state connectivity between the right DLPFC and left-sided regions coupled with normal performance levels in the n-back task and global cognition respectively (Figure 2). These apparent compensatory effects were absent for the left (or dominant) hemisphere, which appeared more susceptible to pathology compared to the right where compensatory processes facilitated normal cognitive function.

However, given the complexity of compensation, our initial approach was perhaps too simplistic, with a focus solely on preHD patients with the highest levels of pathology. Therefore, we modified our
model, moving away from single interactions between brain activity and performance to the long-term trajectory of compensation, modelling the different putative phases of disease progression that may incorporate both the initial onset of compensation and then eventually cessation (41). Using age as our time metric, we proposed three time phases with progressively increasing pathology (Figure 3). Initially, brain activation increases as performance is maintained; then as the disease progresses brain activation plateaus and performance levels begin to deteriorate; finally, with pathology at high levels brain activation and performance both decrease rapidly. In this case, a premanifest cohort as discussed above would likely fall within the first phase of this model, where neuronal loss is ongoing, but activation increased and performance maintained. By eliminating the examination of single interactions between disease load and brain activation, we can place individuals on the compensation trajectory and by modelling as a function of age or time, we can extrapolate this cross-sectional model to look at compensation changes over time. Observational studies typically do not have more than a few years of follow-up, so we make inference about age patterns from both within-subject changes and between-subject differences.

**Conclusion**

Patients performing at normal levels in the presence of structural degeneration and/or pathology is a common feature of neurodegenerative disorders. Recent studies have accordingly identified evidence of such compensation using multimodal MRI, including increased brain activity using task-fMRI, functional connectivity in brain networks using resting-state fMRI and structural connectivity using diffusion imaging in those with mild to moderate levels of disease which desists once pathology becomes too severe. However, no studies have explicitly tested changes in brain activity/connectivity and these changes could simply be related to disease. It is necessary to operationalise compensation in a way that explicitly tests performance and brain changes in the presence of pathology.

**Key points:**

- Compensation has been used to explain maintenance of normal behaviour in the presence of neurodegenerative pathology
- Potential compensatory mechanisms using MRI have been identified in a number of neurodegenerative disorders predominantly in patients with mild to moderate pathology.
- Potential compensation is evident in increased task activation, increased functional network connectivity and anatomical connectivity using a number of imaging modalities.
- Characterisation of compensation for empirical testing requires models that explicitly examine brain activity/connectivity changes, performance and neurodegenerative pathology.
Acknowledgements

The authors wish to thank Rachael Scahill and Eileanoir Johnson for their input.

Financial support and sponsorship

Sarah Gregory, Sarah Tabrizi and Geraint Rees are funded by the Wellcome Trust (Grant reference 200181/Z/15/Z). Jeffrey Long is funded by the CHDI foundation.

Conflicts of interest

None
Figure Legends

Figure 1: Attempted and Successful Compensation

The first (inverted U-shaped relationship between brain activity and neuronal loss) and second (relationship between brain activity and task demands) criteria of attempted compensation are depicted in A and B respectively. The first (positive correlation between brain activity and task performance) and second (altered relationship between brain activity and task performance following disruption or enhancement of the compensating brain region) criteria of successful compensation are depicted in C and D respectively. (A,B) are adapted from Figure 37-3, p. 635, Dennis and Cabeza. *Figure originally published in Frontiers in Psychiatry, 2014: Scheller E et al., Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies 2014.*

Figure 2: Cross-sectional Compensation in Huntington’s Disease

Conditioning plot which illustrates global cognitive performance as a function of connectivity between the right dorsolateral prefrontal cortex and the left hippocampus, conditional on a structural measure of disease load (grey matter volume). The upper panel depicts overlapping ranges of structural disease load that determine the subsample for which observed points are plotted for each associated scatterplot. A linear regression line is fit within each panel. The extreme left scatterplot (red) includes the smallest brain volume (highest structural disease load) range from the data set (lower left red slab). The extreme right scatterplot (blue) includes the largest volume (lowest disease load) range from the data set (upper right blue slab). *Figure originally published in EBioMedicine, 2015: Kloppel S, Gregory S et al., Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study.*

Figure 3: Operationalisation of Compensation in Neurodegeneration

Visualisation of simulated cross-sectional data modelling the three key components including: pathology (volume), compensation (brain activity) and behaviour. Scatterplot of values by age measured at one time point per person. *Figure originally published in Brain, 2017: Gregory S, Long JD, Kloppel S, Razi A, Scheller E, Minkova L, et al. Operationalizing compensation over time in neurodegenerative disease.*


